Jagadeesha's brain, the first juvenile Huntington's Disease donation in India, offers hope for vital neurodegenerative ...

Teva stock rocketed into a profit-taking zone Wednesday after the company put up a big sales beat for its drug Austedo, in ...

Analysts are estimating that Neurocrine Biosciences will report an earnings per share (EPS) of $1.87. Neurocrine Biosciences ...

In after-hours trades, Neurocrine stock rose a fraction to 148.30, peeling back from a stronger gain immediately after the ...

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Good day, everyone, and welcome to today's Neurocrine Biosciences Third Quarter 2025 Results Call.

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaign TD is a chronic movement ...

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares rose 3.3% after the neuroscience-focused biopharmaceutical company reported third-quarter financial results that significantly exceeded ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching 'The Other TD' campaignTD is a chronic movement disorder impacting one in four people who take certain pr ...

A peculiar and uncontrollable mass movement gripped the city of Strasbourg in the summer of 1518 when dozens of residents began dancing in the streets without any apparent reason or music. Historians ...

In Q3, $687 million of its Neurocrine’s income came from sales of Ingrezza, its treatment for the movement disorder tardive dyskinesia, as well as chorea associated with Huntington’s disease. Rounding ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2025.

Victoria Beckham gets candid about her decades-long struggle with an eating disorder in her revealing new Netflix docuseries. In the self-titled docuseries (out now), the fashion designer and former ...